An investigator driven, single-centre randomised, double blind comparative study of standard vs high dose intravenous meropenem, in adult cystic fibrosis patients
D. Clark, J. Armstrong, A. Young, R. Stirling, J. Wilson, D. Spelman, T. Kotsimbos (Melbourne, Australia)
Source: Annual Congress 2010 - New aspects of cystic fibrosis
Session: New aspects of cystic fibrosis
Session type: Thematic Poster Session
Number: 4796
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Clark, J. Armstrong, A. Young, R. Stirling, J. Wilson, D. Spelman, T. Kotsimbos (Melbourne, Australia). An investigator driven, single-centre randomised, double blind comparative study of standard vs high dose intravenous meropenem, in adult cystic fibrosis patients. Eur Respir J 2010; 36: Suppl. 54, 4796
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009
High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial) Source: Eur Respir J, 59 (2) 2102930; 10.1183/13993003.02930-2021 Year: 2022
Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021 Year: 2022
Pivot trial A multicentre randomised controlled equivalence trial comparing oral amoxycillin and intravenous penicillin for community acquired pneumonia in children Source: Eur Respir J 2004; 24: Suppl. 48, 714s Year: 2004
Supplementation of N-acetylcysteine as an adjuvant in treatment of newly diagnosed pulmonary tuberculosis patients: A prospective, randomized double blind, placebo controlled study Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial. Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
Paracetamol increases airway resistance in stable asthmatics: A double blind, randomized, placebo controlled study Source: Annual Congress 2010 - New or old physiological parameters in chronic airway disorders? Year: 2010
Acetylcysteine in treatment of subacute sinusitis, a double blind placebo controlled clinical trial study Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 674s Year: 2007
A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001
A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019
Feasibility of shortening intravenous antibiotic therapy for bronchiectasis based on bacterial load: a proof-of-concept randomised controlled trial Source: Eur Respir J, 58 (6) 2004388; 10.1183/13993003.04388-2020 Year: 2021
Comparative effect of backpack carrying on cystic fibrosis and healthy children: a randomized crossover controlled trial Source: International Congress 2017 – Cystic fibrosis: clinical issues Year: 2017
Analysis of the efficacy of moxifloxacin for the treatment of bronchial colonization in COPD patients using microbial molecular typing: a randomized, double-blind, placebo-controlled study Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019
The effect of high dose N-acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients — A double blinded randomized placebo controlled trial Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Late-breaking abstract: The effects of roxithromycin as anti-inflammatoy agent on clinical outcomes in patient with bronchiectasis: A double blinded randomized controlled study Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011